- A researcher at Intermountain Medical Center recently contributed to a major report on the utility of a new method for improving tricuspid valve function.
- An oncologist at St. Vincent Healthcare in Billings, Montana, led a review of the evidence for a new drug potentially capable of replacing rituximab — the monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.
- Researchers across infection prevention, pulmonary/critical care, and maternal fetal medicine are contributing to the ongoing effort to better understand COVID-19 vaccine efficacy. Recent publications include a CDC-funded study of mRNA vaccines against moderate and severe COVID-19 in adults, updated data on booster shots doubling the efficacy of the original series, and an evaluation of the efficacy of vaccination among pregnant people, a typically high-risk population.
- Intermountain developed a remote home monitoring system for managing patients with low oxygen related to COVID-19. Harris Carmichael, MD, led the report from this multidisciplinary group demonstrating how well the program worked. Additionally, Nathan Starr of Intermountain and Castell’s hospital-level Care at Home program led an overview of our highly effective program for home-based hospital services.
- Kathleen McKee, MD, neurologist and co-chair for the Research Equity Committee, published a call-to-action for the inclusion of non-English-speaking participants in clinical trials. Dr. McKee is leading by doing with the launch of the SPARX3 trial which is investigating the role of an exercise program for the treatment of Parkinson Disease.
Leave a comment on Yammer.
